Key result
18F-FDG uptake was significantly higher in bone sarcomas (median SUVmax 6.9 g/mL) than in soft tissue sarcomas (median 2.5 g/mL, P=0.03), and higher in osteosarcoma than Ewing sarcoma (P=0.009).
Why the study?
What is the degree of 18F-FDG uptake in pediatric bone and soft tissue sarcomas?
Observational (n=29)
What is the degree of 18F-FDG uptake in pediatric bone and soft tissue sarcomas?
Pediatric sarcomas, particularly osteosarcomas, demonstrate sufficient 18F-FDG uptake to potentially allow for monitoring of therapeutic responses using PET/CT imaging.
Answers are grounded in this paper and cite their sources.
May support PET/CT response monitoring in pediatric osteosarcoma; leaves open prospective validation before clinical adoption.
A high (18)F-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) imaging in sarcomas of adults has been reported. The current study aimed at defining the degree of (18)F-FDG uptake of pediatric sarcomas. This retrospective study included 29 patients (23 males, 6 females; mean age 14 ± 5 years) with soft tissue (n = 9) or bone (n = 20) sarcomas. Twenty-two patients (76%) underwent (18)F-FDG PET/CT and 7 (24%) had dedicated (18)F-FDG PET studies. Tumor (18)F-FDG uptake was quantified by standard uptake value (SUV)(max) and tumor-to-liver ratios (SUV ratios; tumor SUV(max)/liver SUV(mean)). Tumor SUV(max) and SUV ratios were correlated with tumor Ki-67 expression. SUV(max) ranged from 1.4 to 24 g/mL (median 2.5 g/mL) in soft tissue sarcomas and 1.6 to 20.4 g/mL (median 6.9 g/mL) in bone sarcomas (P = .03), and from 1.6 to 9.2 g/mL (median 3.9 g/mL) and 3.5 to 20.4 g/mL (median 12 g/mL) in Ewing sarcoma and osteosarcoma, respectively (P = .009). Tumor SUV ratios ranged from 0.8 to 8.7 (median 1.9) in soft tissue sarcomas and 1.4 to 8.9 (median 3.8) in bone sarcomas (P = .08). Ewing sarcoma had a significantly lower tumor SUV ratio than osteosarcoma (P = .01). Ki-67 expression correlated significantly with the (18)F-FDG uptake in bone but not in soft tissue sarcomas. All sarcomas were visualized by (18)F-FDG PET/CT imaging. A higher (18)F-FDG uptake was observed in osteosarcoma than in Ewing and soft tissue sarcomas. The results of this study suggest that the degree of tumor (18)F-FDG uptake is sufficient to allow for monitoring of therapeutic responses in pediatric sarcomas.
No takes yet. Share an insight, caveat, or question.
Walter et al. (2011) conducted an observational in Pediatric sarcomas (n=29). Bone sarcomas vs. Soft tissue sarcomas was evaluated on Tumor 18F-FDG uptake (median SUVmax in g/mL) (p=0.03). 18F-FDG uptake was significantly higher in bone sarcomas (median SUVmax 6.9 g/mL) than in soft tissue sarcomas (median 2.5 g/mL, P=0.03), and higher in osteosarcoma than Ewing sarcoma (P=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: